{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:11:27Z","timestamp":1779153087488,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-026-02311-5","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:51:10Z","timestamp":1775555470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal radiomics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: integration of amide proton transfer weighted imaging in radiomics"],"prefix":"10.1186","volume":"26","author":[{"given":"Mingzhe","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongqiu","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangguang","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinrong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"3","key":"2311_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA: Cancer J Clinicians"},{"issue":"9938","key":"2311_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"key":"2311_CR3","doi-asserted-by":"crossref","unstructured":"Pesapane F, Rotili A, Scalco E, Pupo D, Carriero S, Corso F, et al. Predictive value of tumoral and peritumoral radiomic features in neoadjuvant chemotherapy response for breast cancer: a retrospective study. Radiol Med. 2025.","DOI":"10.1007\/s11547-025-01969-1"},{"issue":"3","key":"2311_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1148\/radiol.12110748","volume":"263","author":"NM Hylton","year":"2012","unstructured":"Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657\/I-SPY TRIAL. Radiology. 2012;263(3):663\u201372.","journal-title":"Radiology"},{"issue":"1","key":"2311_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-024-07484-7","volume":"209","author":"LM Janssen","year":"2025","unstructured":"Janssen LM, de Vries B, Janse MHA, van der Wall E, Elias SG, Salgado R, et al. Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2025;209(1):167\u201375.","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"2311_CR6","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.3390\/cancers13143521","volume":"13","author":"A Romeo V","year":"2021","unstructured":"Romeo A V, Perillo G, Basso T, Garbino L, Nicolai N, Maurea E, et al. Assessment and prediction of response to neoadjuvant chemotherapy in breast cancer: a comparison of imaging modalities and future perspectives. Cancers. 2021;13(14):3521.","journal-title":"Cancers"},{"key":"2311_CR7","doi-asserted-by":"crossref","unstructured":"Zhang X, Wang D, Liu Z, Wang Z, Li Q, Xu H, Zhang B, et al. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer. Quant Imag Med Surg. 2020;10(1):197\u2013210.","DOI":"10.21037\/qims.2019.11.16"},{"key":"2311_CR8","doi-asserted-by":"publisher","first-page":"1366613","DOI":"10.3389\/fonc.2024.1366613","volume":"14","author":"Q Hu","year":"2024","unstructured":"Hu Q, Hu Y, Ai H, Xia L, Liu R, Ai T. Pre-operative MRI in evaluating pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer: a study focused on influencing factors of baseline clinical-pathological and imaging features. Front Oncol. 2024;14:1366613.","journal-title":"Front Oncol"},{"key":"2311_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fonc.2020.00093","volume":"10","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Huang J, Liang J, Ma M, Ye K, Shi C, et al. The diagnostic performance of DCE-MRI in evaluating the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Front Oncol. 2020;10:93.","journal-title":"Front Oncol"},{"issue":"9","key":"2311_CR10","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1007\/s00268-019-05032-9","volume":"43","author":"N Yu","year":"2019","unstructured":"Yu N, Leung VWY, Meterissian S. MRI performance in detecting pCR after neoadjuvant chemotherapy by molecular subtype of breast cancer. World J Surg. 2019;43(9):2254\u201361.","journal-title":"World J Surg"},{"issue":"2","key":"2311_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","volume":"4","author":"MB Lobbes","year":"2013","unstructured":"Lobbes MB, Prevos R, Smidt M, Tjan-Heijnen VC, van Goethem M, Schipper R, et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imag. 2013;4(2):163\u201375.","journal-title":"Insights Imag"},{"issue":"3","key":"2311_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.acra.2023.10.026","volume":"31","author":"Y Chen","year":"2024","unstructured":"Chen Y, Li J, Zhang J, Yu Z, Jiang H. Radiomic nomogram for predicting axillary lymph node metastasis in patients with breast cancer. Academic Radiol. 2024;31(3):788\u201399.","journal-title":"Academic Radiol"},{"issue":"1","key":"2311_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12935-024-03587-9","volume":"24","author":"H Shan","year":"2024","unstructured":"Shan H, Ke T, Bao S, Liu Y, Tan N, Zhou X, et al. Evaluation of functional magnetic resonance APT and DKI imaging for breast cancer. Cancer Cell Int. 2024;24(1):401.","journal-title":"Cancer Cell Int"},{"key":"2311_CR14","doi-asserted-by":"publisher","first-page":"1295478","DOI":"10.3389\/fmed.2024.1295478","volume":"11","author":"N Zhang","year":"2024","unstructured":"Zhang N, Song Q, Liang H, Wang Z, Wu Q, Zhang H, et al. Early prediction of pathological response to neoadjuvant chemotherapy of breast tumors: a comparative study using amide proton transfer-weighted, diffusion weighted and dynamic contrast enhanced MRI. Front Med. 2024;11:1295478.","journal-title":"Front. Med"},{"key":"2311_CR15","doi-asserted-by":"crossref","unstructured":"Cao Y, Wang X, Li L, Shi J, Zeng X, Huang Y, Chen H, Jiang F, et al. Early prediction of pathologic complete response of breast cancer after neoadjuvant chemotherapy using longitudinal ultrafast dynamic contrast-enhanced MRI. Diagn Interv Imag. 2023;104(12):605\u201314.","DOI":"10.1016\/j.diii.2023.07.003"},{"key":"2311_CR16","doi-asserted-by":"crossref","unstructured":"Meng N, Wang X, Sun J, Han D, Bai Y, Wei W, Wang Z, et al. A comparative study of the value of amide proton transfer-weighted imaging and diffusion kurtosis imaging in the diagnosis and evaluation of breast cancer. Eur Radiol. 2021;31(3):1707\u201317.","DOI":"10.1007\/s00330-020-07169-x"},{"key":"2311_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mri.2023.10.010","volume":"105","author":"T Yu","year":"2023","unstructured":"Yu T, Li L, Shi J, Gong X, Cheng Y, Wang W, et al. Predicting histopathological types and molecular subtype of breast tumors: a comparative study using amide proton transfer-weighted imaging, intravoxel incoherent motion and diffusion kurtosis imaging. Magn Reson Imag. 2023;105:37\u201345.","journal-title":"Magn Reson Imag"},{"key":"2311_CR18","doi-asserted-by":"crossref","unstructured":"Li Z, Li J, Lu X, Qu M, Tian J, Lei J. The diagnostic performance of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in evaluating the pathological response of breast cancer to neoadjuvant chemotherapy: a meta-analysis. Eur J Radiol. 2021;143:109931.","DOI":"10.1016\/j.ejrad.2021.109931"},{"key":"2311_CR19","doi-asserted-by":"crossref","unstructured":"Zhang S, Liu Y, Liu X, Liu Y, Zhang J. Prognoses of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer receiving neoadjuvant chemotherapy before surgery: a retrospective analysis. Cancers. 2023;15(4):1157.","DOI":"10.3390\/cancers15041157"},{"issue":"3","key":"2311_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-023-07152-2","volume":"203","author":"D Moldoveanu","year":"2024","unstructured":"Moldoveanu D, Hoskin TL, Day CN, Schulze AK, Goetz MP, Boughey JC. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+\/Her2- breast cancer. Breast Cancer Res Treat. 2024;203(3):419\u201328.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2311_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000530584","volume":"18","author":"M Balic","year":"2023","unstructured":"Balic M, Thomssen C, Gnant M, Harbeck N. St. Gallen\/Vienna, 2023: optimization of treatment for patients with primary breast cancer - a brief summary of the Consensus Discussion. Breast Care (Basel, Switz). 2023;18(3):213\u201322.","journal-title":"Breast Care (Basel, Switz)"},{"key":"2311_CR22","doi-asserted-by":"crossref","unstructured":"Song Y, Zhang J, Zhang YD, Hou Y, Yan W X, Zhou Y, et al. FeAture Explorer (FAE): a tool for developing and comparing radiomics models. PLoS ONE. 2020;15(8):e0237587.","DOI":"10.1371\/journal.pone.0237587"},{"issue":"6","key":"2311_CR23","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1007\/s00330-021-08462-z","volume":"32","author":"NA Hottat","year":"2022","unstructured":"Hottat NA, Badr DA, Lecomte S, Besse-Hammer T, Jani JC, Cannie MM. Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements. Eur Radiol. 2022;32(6):4067\u201378.","journal-title":"Eur Radiol"},{"issue":"4","key":"2311_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","volume":"1","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448\u201354.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2311_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson A V, Agnese R, Allison D, et al. Breast cancer, version 3. 2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN. 2024;22(5):331\u201357.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"3","key":"2311_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/cco-20-123","volume":"9","author":"M Takada","year":"2020","unstructured":"Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020;9(3):32.","journal-title":"Chin Clin Oncol"},{"issue":"7528","key":"2311_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"key":"2311_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.humpath.2018.05.024","volume":"80","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wang XI, Zhang S. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer. Hum Pathol. 2018;80:47\u201354.","journal-title":"Hum Pathol"},{"issue":"17","key":"2311_CR29","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.3390\/cancers13174271","volume":"13","author":"F Pesapane","year":"2021","unstructured":"Pesapane F, Rotili A, Botta F, Raimondi S, Bianchini L, Corso F, et al. Radiomics of MRI for the prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients: a single referral centre analysis. Cancers. 2021;13(17):4271.","journal-title":"Cancers"},{"issue":"12","key":"2311_CR30","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1016\/j.acra.2024.06.004","volume":"31","author":"C Xu","year":"2024","unstructured":"Xu C, Wang Z, Wang A, Zheng Y, Song Y, Wang C, et al. Breast cancer: multi-b-value diffusion weighted habitat imaging in predicting pathologic complete response to neoadjuvant chemotherapy. Academic Radiol. 2024;31(12):4733\u201342.","journal-title":"Academic Radiol"},{"issue":"1","key":"2311_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","volume":"17","author":"J Lin","year":"2024","unstructured":"Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17(1):6.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2311_CR32","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1172\/JCI67230","volume":"123","author":"GL Semenza","year":"2013","unstructured":"Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664\u201371.","journal-title":"J. Clin. Invest"},{"key":"2311_CR33","doi-asserted-by":"crossref","unstructured":"Palazon A, Goldrath AW, Nizet V. HIF transcription factors, inflammation, and immunity. Immunity. 2014;41(4):518\u201328.","DOI":"10.1016\/j.immuni.2014.09.008"},{"issue":"19","key":"2311_CR34","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"O Tr\u00e9dan","year":"2007","unstructured":"Tr\u00e9dan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2311_CR35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113(7):808\u201319.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2311_CR36","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.surg.2014.01.009","volume":"155","author":"A Sueta","year":"2014","unstructured":"Sueta A, Yamamoto Y, Hayashi M, Yamamoto S, Inao T, Ibusuki M, et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: Is it equally useful across tumor subtypes? Surgery. 2014;155(5):927\u201335.","journal-title":"Surgery"},{"issue":"4","key":"2311_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/his.12412","volume":"65","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Wang J, Skinner KA, Shayne M, Hajdu SI, Bu H, et al. Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression. Histopathology. 2014;65(4):508\u201316.","journal-title":"Histopathology"},{"key":"2311_CR38","doi-asserted-by":"crossref","unstructured":"Raphael J, Gandhi S, Li N, Lu FI, Trudeau M. The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy. Breast cancer research and treatment. 2017;164(2):285\u201394.","DOI":"10.1007\/s10549-017-4269-6"},{"issue":"3","key":"2311_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W, Verma H V, Suzanne Klimberg S V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559\u201367.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2311_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/jclinpath-2015-202985","volume":"69","author":"N Melling","year":"2016","unstructured":"Melling N, Kowitz CM, Simon R, Bokemeyer C, Terracciano L, Sauter G, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016;69(3):209\u201314.","journal-title":"J Clin Pathol"},{"issue":"5","key":"2311_CR41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s10434-001-0418-5","volume":"8","author":"NK Kim","year":"2001","unstructured":"Kim NK, Park JK, Lee KY, Yang WI, Yun SH, Sung J, et al. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol. 2001;8(5):418\u201324.","journal-title":"Ann Surg Oncol"},{"key":"2311_CR42","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","volume":"72","author":"F Borri","year":"2021","unstructured":"Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136\u201345.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2311_CR43","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41416-023-02451-3","volume":"129","author":"S Makhlouf","year":"2023","unstructured":"Makhlouf S, Wahab N, Toss M, Ibrahim A, Lashen AG, Atallah NM, et al. Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence. Br J Cancer. 2023;129(11):1747\u201358.","journal-title":"Br J Cancer"},{"issue":"8","key":"2311_CR44","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11547-024-01853-4","volume":"129","author":"R Nardone V","year":"2024","unstructured":"Nardone R V, Rubini A, Gagliardi D, Del Tufo F, Belfiore S, Boldrini MP, et al. Delta radiomics: an updated systematic review. Radiol Med. 2024;129(8):1197\u2013214.","journal-title":"Radiol Med"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02311-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02311-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02311-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:46:53Z","timestamp":1779151613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02311-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2311"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02311-5","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Committee of the Affiliated Cancer Hospital of Zhengzhou University (No0.2024\u2013170-001). The requirement for informed consent from patients was waived in accordance with Article 39 of the\n                      Administrative Measures for Ethical Review of Biomedical Research Involving Humans\n                      (Order No. 11, National Health and Family Planning Commission of China), as the study used anonymized MRI data previously obtained for clinical purposes and involved no risk, privacy, or commercial interest to the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as all images in this study did not any show personal information of patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}